Practice · Dosing & titration

When a dose reduction is the correct response to a side effect

Practice › Dosing & titration dose reduction tirzepatide titration missed dose semaglutide worked example

Solved

Solved by g.danquah in post #6

Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice. The…

Jump to the accepted answer →

v.malinowskiTL215 Feb 2026#1

When a dose reduction is the correct response to a side effect — that is the question, and I have not found it answered plainly anywhere I have looked.

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: tirzepatide, 22 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 11 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

0 likes 5mo

s.radichTL223 Feb 2026 · edited#2

The opening post put the caveat in the right place and I want to underline it.

Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of once-weekly dosing. The trade-off is convenience versus a slightly flatter concentration curve.

2 likes 5mo

MakinenTL2Member2 Mar 2026#3

Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one.

The honest answer is that it depends, and here is what it depends on.

13 likes 5mo

j.solbergTL27 Mar 2026#4

Useful. I have added it to my own notes with the date on it.

27 likes 5mo

titration_diaryTL3Regular13 Mar 2026#5

s.radich, post #2: The opening post put the caveat in the right place and I want to underline it. Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a weekly dosing schedule. Splitting it flattens the curve further but loses the convenience of… Go to post

Taking post #3 at face value and following it one step further.

Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on.

0 likes in reply to #2 5mo

g.danquahTL2 Solution18 Mar 2026#6

Makinen, post #3: Escalating before steady state means you are judging a dose you have not yet fully experienced. That is the whole argument against compressing the schedule and it is a good one. The honest answer is that it depends, and here is what it depends on. Go to post

Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice.

The mechanism is plausible, which is not the same as established.

11 likes in reply to #3 4mo

BuchholzTL2Member22 Mar 2026#7

Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum.

That holds for the case as described. Change the assumptions and it may not.

19 likes 4mo

f.espinozaTL227 Mar 2026#8

Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened.

That is the version I use. It may not be the version that is correct.

0 likes 4mo

dr_bhattacharyaTL3Physician31 Mar 2026#9

f.espinoza, post #8: Writing down the date, the dose and the site each week takes fifteen seconds and is the single most useful record anyone here keeps. Memory reconstructs a titration history that never happened. That is the version I use. It may not be the version that is correct. Go to post

Holding a dose indefinitely: the trials did not study indefinite holding at a non-maximum dose. The trials escalated to a target and then held that. What happens if you stay at an intermediate dose for years is not formally studied and extrapolation is the best available reasoning.

Worth reading the earlier posts in this thread before acting on mine.

2 likes in reply to #8 4mo

t.duarteTL24 Apr 2026#10

Reaching a dose and staying there for a year: the question of whether a stable dose remains effective over years is mostly answered by the withdrawal trials and by real-world reports. The dose does not seem to stop working, but the longest trials are not indefinitely long.

The confident version of this sentence would be wrong, so here is the hedged one.

8 likes 4mo

f.novakTL29 Apr 2026#11

Collapsed as off-topic by two members at trust level 3 or above

I read post #9 twice before replying, because I had assumed the opposite.

Dose equivalence between different incretin analogues is a weak concept. The molecules differ in structure, half-life, receptor selectivity, and in what has been studied clinically. One mg of semaglutide is not equivalent to one mg of something else in any meaningful sense.

I am reporting what happened, not recommending it.

trough_indexTL3Regular13 Apr 2026#12

j.solberg, post #4: Useful. I have added it to my own notes with the date on it. Go to post

I came in to disagree and I am leaving without a disagreement.

23 likes in reply to #4 3mo

a.norgaardTL217 Apr 2026#13

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

Anyone who has looked at this more carefully, please correct the record.

10 likes 3mo

buffer_reviewTL3Regular21 Apr 2026#14

Taking post #13 at face value and following it one step further.

If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.

That has held every time I have looked, which is not the same as always.

3 likes 3mo

ne.laurentTL225 Apr 2026#15

How the published trials escalated: they used specific step sizes and intervals. The STEP programme used a particular cadence; the SURPASS and SURMOUNT programmes used slightly different ones. Reading them side by side shows the variation is real but small.

0 likes 3mo

LJankowiakTL3Regular28 Apr 2026#16

Buchholz, post #7: Holding at a dose that is working is a legitimate position and it is not what the trial protocols did. The protocols escalated to a target because they were measuring the target dose, not finding each person's minimum. That holds for the case as described. Change the assumptions and it may not. Go to post

The arithmetic of an intermediate dose: if the label says 1.0 mg and 2.0 mg, a dose strictly between them is off-label by definition. Some people compute it anyway. The reasoning is pharmacological — e.g., "I will split the difference between steps" — but it is reasoning from theory, not from evidence.

31 likes in reply to #7 3mo

mi.amankwahTL22 May 2026 · edited#17

Worth separating two things that post #13 runs together.

Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.

I am not the right person to answer the follow-up to this.

16 likes 3mo

ambient_draftTL3Regular6 May 2026#18

This follows post #17 rather than contradicting it.

A missed dose in a weekly schedule is not a trough to chase. With a week-long half-life you are perturbing a slowly moving average, and the labelling for licensed products in this class says take it if the next dose is far enough away and skip it otherwise.

6 likes 3mo

c.bakkerTL210 May 2026#19

g.danquah, post #6: Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose well, others escalate on the prescribed schedule regardless. The published trials used a calendar-based schedule. Tolerability-based escalation has no formal evidence base but is not uncommon in practice. The mechanism is plausible,… Go to post

This settles it for me, at least until somebody posts a reason it should not.

1 like in reply to #6 3mo

j.nascimentoTL213 May 2026#20

Collapsed as off-topic by two members at trust level 3 or above

Confirming post #17 from a second method, which matters more than confirming it from a second person.

The maximum studied dose is a fact about the trial and not a ceiling on the molecule. It is also the last point at which anything is known, which is the reason to treat it as one.

I looked this up rather than remembered it, which is the right order.

physio_marchettiTL2Physiotherapist17 May 2026#21

Narrowing post #18, because the general version has more than one answer.

Dose and effect are not linear across the studied range for every compound in this class. Assuming a doubled dose gives a doubled effect is the reasoning error behind most disappointment.

Someone should write this up properly, and it should probably not be me.

0 likes 2mo

j.iyerTL220 May 2026#22

Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.

2 likes 2mo

baseline_driftTL2Analytical chemist24 May 2026#23

When a dose reduction is the correct response to a side effect: if a side effect is dose-dependent (nausea, constipation, injection discomfort), reducing the dose is a reasonable response. If the side effect is not dose-dependent (e.g., hypoglycemia with insulin), dose reduction does not address the issue.

13 likes 2mo

n.oseiTL227 May 2026#24

titration_diary, post #5: Taking post #3 at face value and following it one step further. Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose. Escalating before steady state means escalating on incomplete information about the dose you are on. Go to post

If you are stepping up mainly because the schedule says so rather than because the current dose has stopped doing what you wanted, that is worth noticing before rather than afterwards.

Two people can read the same figure differently here and both be reasonable.

28 likes in reply to #5 2mo

two_year_lineTL3Regular31 May 2026#25

a.norgaard, post #13: The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing. Anyone who has looked at this more carefully, please correct the record. Go to post

If symptoms reset at each step, that is the expected pattern rather than a sign that the previous adaptation was imaginary. Every dose increase is a new exposure.

0 likes in reply to #13 2mo

au.pereiraTL23 Jun 2026#26

Going back down a step is not a failure and the trials allowed it. Several protocols permitted a return to the previous dose for tolerability and then a second attempt at the step.

5 likes 2mo

coldchain_liuTL3Regular6 Jun 2026 · edited#27

One more caveat and then I will stop qualifying: the sample selected itself.

19 likes 2mo

s.kuuselaTL210 Jun 2026#28

Post #24 and I disagree about the size of the effect, not about the direction.

I would want the raw data before agreeing with my own summary of it.

0 likes 2mo

l.wikstromTL213 Jun 2026#29

The starting dose in most of these programmes is a tolerance step and produces little effect by design. Judging the compound at the starting dose is judging the wrong thing.

The right answer here may simply be that it has not been measured.

29 likes 1mo

a.ibarraTL216 Jun 2026#30

The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant. The pharmacological argument is that with a week-long half-life, four weeks approaches steady state and you can assess the dose fairly. That is an argument for not going faster. It is not an argument against going slower.

The short answer was in the first line; everything after is the working.

0 likes 1mo

Sponsored Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing → Sponsored GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →